



**PRIVATE FUNDING OPPORTUNITIES: AUG 26, 2016**

---

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

**1. Arnold O. Beckman Postdoctoral Fellows Award Program, Arnold and Mabel Beckman Foundation**

The Arnold O. Beckman Postdoctoral Fellows Award program is an open program for research institutions across the United States to support postdoctoral scholars who are judged to have the highest potential for success in an independent academic career in chemistry and the life sciences, and who will become the next generation of leaders and innovators in science, engineering, and technology. It is the Foundation's intent that the Arnold O. Beckman Postdoctoral Fellowship will be the catalyst to aid in the fellow's transition to an outstanding, independent research career.

Arnold O. Beckman Postdoc Fellows must be mentored throughout the term of the award, meet regularly with their sponsoring faculty mentor, and devote 100% of their effort to the project outlined in the Arnold O. Beckman Postdoctoral Fellows application.

Award Amount: \$134,000 paid over 2 years

Application Deadline: Sep 19, 2016

Website: <http://www.beckman-foundation.org/programs/beckman-postdoctoral-fellows>

**2. Beckman-Argyros Award in Vision Research, Arnold and Mabel Beckman Foundation**

The Beckman-Argyros Award in Vision Research is intended to reward one individual who has made significant transformative breakthroughs in vision research; this may include those whose contributions to science in general, or through the development of an innovative technology or fundamental scientific breakthrough have been applied to, aided and/or improved the vision sciences.

The Beckman-Argyros Award in Vision Research is an annual award established in 2013 to honor and celebrate a decades-long friendship of the two remarkable men, Dr. Arnold O. Beckman and Ambassador George L. Argyros, and to continue their commitment, dedication and shared vision to make the world a better place. The Beckman-Argyros Award honors Ambassador Argyros for his 22 years of service as Chairman of the Board of the Arnold and



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <[arobb@mgh.harvard.edu](mailto:arobb@mgh.harvard.edu)> to schedule an individual consultation or group training session.

Mabel Beckman Foundation and recognizes the special and unique friendship he shared with Arnold O. Beckman for over forty years.

The Nominee's research must:

- show demonstrated and quantifiable success in the number of people who have actually or will potentially benefit by the research;
- be novel, original and the underlying fundamental character of the technical idea or concept must be identified;
- show how the research has removed fundamental barriers or constraints to incremental improvements and refinement or that it embodies wholly new scientific principles; and
- show potential result in transformative breakthroughs in vision research.

A commitment of at least 50% of the Nominee's time to further this research is required following the receipt of the funding, to be used over a three-year period.

Award Amount: \$500,000 paid over 3 years

Nomination Deadline: Sep 30, 2016

Website: <http://www.beckman-foundation.org/programs/beckman-argyros-vision-program-information>

### **3. Pioneering Ideas Brief Proposals, Robert Wood Johnson Foundation (RWJF)**

Throughout the year, RWJF welcomes Pioneering Ideas Brief Proposals that can help the Foundation anticipate the future and consider new and unconventional perspectives and approaches to building a Culture of Health.

Featured Calls for Ideas: While the Pioneering Ideas Brief Proposal is an open call for ideas, from time to time RWJF may also feature opportunities related to specific topics it is interested in exploring. The current featured topics are "Reinventing Discovery" and "The Future of Work."

#### Reinventing Discovery

Health and medical research drives discovery, development and delivery of new diagnostics and technologies. However, it is often slow, opaque and does not include experiences and insights from practitioners, people and communities. Through strides in health information technology, Big Data and social media, RWJF believes there is a growing opportunity to change stakeholder engagement in and the organization of biomedical research.

RWJF is interested in producing more rapid, responsive and relevant research - and believe that new models, which are open, collaborative and inclusive of patient/consumer/citizen input, can help us get there. RWJF is looking for projects that pilot or use tools which help to share data and promote open science, and also emphasize the value of patient and citizen engagement to health and medical discovery.

For this specific area of exploration, RWJF is not seeking to support the development of new platforms, projects to advance interoperability of health information technology, or biomedical research experiments. Projects can include, but are not limited to:

- Patient and consumer engagement activities, including tools and processes that enable consumers and patients to help frame or refine research questions, with a focus on equity
- Development and assessment of approaches to return results to patients and consumers
- Development of inclusive governance models and models of sustainability

### The Future of Work

The way that we work is rapidly changing... again. There has always been an iterative relationship between technology, society, employment and health - we saw it with the rise and fall of jobs related to the industrial revolution and with the introduction of digital technologies like the internet and e-mail. Issues like job security, economic stability, work-life balance and the role of the employer mean very different things now than they did 50 years ago. What will the changes we're seeing now mean for work in the next 50 years, and what effects will they have on our health?

What is a Pioneering Idea?

Good question! RWJF doesn't want to provide a checklist that limits applicants' thinking - or the Foundation's. RWJF does want to give applicants as clear a picture as it can about the kinds of proposals the Foundation hopes to see, so applicants can best assess whether submitting an idea through the Foundation's Pioneering Ideas Brief Proposal process is the right next step for them.

Award Amount: \$250,000 for up to 18 months

Preliminary Proposal Deadline: Sep 1, 2016

Website: <http://www.rwjf.org/en/how-we-work/submit-a-proposal.html>

#### **4. Established Investigator Awards, Melanoma Research Alliance (MRA)**

The MRA is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment.

MRA welcomes proposals in the following areas:

- Prevention: Elucidation of environmental, epidemiological, and biological factors in melanoma genesis that lead to prevention strategies .
- Detection, Diagnosis , and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
- Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma . Examples include but are not limited to studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms

involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas: For the 2016-2017 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

1. Addressing treatment failures or difficult-to-treat disease, which may include rare melanoma subtypes or metastatic brain disease, by undertaking studies leading to new targets and/or rational treatment approaches
2. Informing logical and optimal combination therapies, therapeutic sequences, or treatment regimens, including defining dose or duration of targeted and /or immunotherapies
3. Developing markers of response, resistance, or risk of recurrence or death in early stage disease to improve clinical decision - making and speed the development of new melanoma therapies in the neoadjuvant, adjuvant, or advanced setting
4. Identifying new targets, treatments, or biomarkers via the study of exceptional responders/non - responders and/or leveraging data (e.g. clinical, genomics, and immunologic) from within and outside melanoma.

*Please note:* Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.

Award Amount: \$375,000 for up to 3 years

Application Deadline: Oct 21, 2016

Website: <http://www.curemelanoma.org/research/request-for-proposals/>

## **5. Young Investigator Awards, Melanoma Research Alliance (MRA)**

This program aims to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma researchers.

MRA welcomes proposals in the following areas:

- Prevention: Elucidation of environmental, epidemiological, and biological factors in melanoma carcinogenesis.
- Detection, Diagnosis, and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
- Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include but are not limited to studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas: For the 2016-2017 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

- 1) Addressing treatment failures or difficult-to- treat disease, which may include rare melanoma subtypes or metastatic brain disease, by undertaking studies leading to new targets and/or rational treatment approaches
- 2) Informing logical and optimal combination therapies, therapeutic sequences, or treatment regimens, including defining dose or duration of targeted and /or immunotherapies
- 3) Developing markers of response, resistance, or risk of recurrence or death i n early stage disease to improve clinical decision - making and speed the development of new melanoma therapies in the neoadjuvant, adjuvant, or advanced setting
- 4) Identifying new targets, treatments , or biomarkers via the study of exceptional responders/non - responders and/or leveraging data (e.g. clinical, genomics , and immunologic) from within and outside melanoma

*Please note:* Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.

Award Amount: \$225,000 paid over 3 years

Eligibility Confirmation Deadline: Oct 14, 2016

Proposal Deadline: Oct 21, 2016

Website: <http://www.curemelanoma.org/research/request-for-proposals/>

## **6. Established Investigator Academic-Industry Partnership Awards, Melanoma Research Alliance (MRA)**

The MRA is soliciting proposals that address the gap in translational science, i.e., turning scientific discoveries into tools and/or treatments for high risk individuals and melanoma patients. Successful proposals will offer the potential for translational development that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment.

The Established Investigator Awards are designed to facilitate progress via interactions between the academic and industrial research sectors, and will be co-funded by MRA and an industrial collaborator whose involvement is essential to the project.

It is the responsibility of the academic scientist to find an industrial partner whose involvement and collaboration will be vital to conducting the research project, or vice versa.

MRA welcomes proposals in the following areas:

- Prevention: Elucidation of environmental, epidemiological and biological factors in melanoma carcinogenesis.
- Diagnosis and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
- Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma are solicited. Examples include, but are not limited to, studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas For the 2016 - 2017 cycle

MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

1. Addressing treatment failures or difficult-to- treat disease, which may include rare melanoma subtypes or metastatic brain disease, by undertaking studies leading to new targets and/or rational treatment approaches
2. Informing logical and optimal combination therapies, therapeutic sequences, or treatment regimens, including defining dose or duration of targeted and /or immunotherapies
3. Developing markers of response, resistance, or risk of recurrence or death in early stage disease to improve clinical decision - making and speed the development of new melanoma therapies in the neoadjuvant, adjuvant, or advanced setting
- 5) Identifying new targets, treatments , or biomarkers via the study of exceptional responders/non - responders and/or leveraging data (e.g. clinical, genomics , and immunologic) from within and outside melanoma

*Please note:* Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.

Award Amount: \$300,000 for up to 3 years

Proposal Deadline: Oct 21, 2016

Website: <http://www.curemelanoma.org/research/request-for-proposals/>

**7. Geriatrics Project (Irma and Paul Milstein Program for Senior Health), Milstein Medical Asian American Partnership Foundation (MMAAP Foundation)**

In connection with the Foundation's committed support of outstanding research in geriatric medicine and senior health, it invites submission of applications from for one research project, which will have immediate impact on improving senior health in China. The MMAAP Foundation will be providing the sole support for these initiatives.

The aim of the program is to build enduring partnerships between the US and Asia by funding a research project which will have immediate impact on improving senior health in China.

Funds may be used for support of a new or ongoing clinical research project with demonstrated potential for immediate impact on improving senior health in China.

The successful application should include a stated goal of establishing a partnership between the US and Chinese institutions to facilitate a long-term relationship and a feasible plan for continuing collaboration.

Award Amount: \$60,000 paid over 2 years

Application Deadline: Dec 1, 2016

Website: <http://www.mmaapf.org/en/grants/>

#### **8. Translational Medicine Project (Research Project Award in Translational Medicine), Milstein Medical Asian American Partnership Foundation (MMAAP Foundation)**

In connection with the Foundation's committed support of outstanding medical research in translational medicine, it invites submission of applications from Chinese medical researchers for a research project award which will have immediate impact on improving health in China. The MMAAP Foundation will be providing the sole support for these initiatives.

Translational Medicine refers to the process of converting scientific discoveries into drugs or medical devices to treat patients. The process includes preclinical studies, observational studies, testing treatment methods and the development of best practices of the treatment.

The aim of the program is to build enduring partnership between the US and Asia through funding a research project and to encourage long-term collaborations between the two regions.

Funds may be used for support of a new or ongoing clinical research project with demonstrated potential for immediate impact on improving health in China. Knowledge gained should be applicable to clinical practice with clear generalizability.

The successful application should include a stated goal of establishing a partnership between the US and Chinese institutions to facilitate a long-term relationship and a feasible plan for further collaboration.

Award Amount: \$60,000 paid over 2 years

Application Deadline: Dec 1, 2016

Website: <http://www.mmaapf.org/en/grants/>

#### **9. Research Grants, Oxalosis and Hyperoxaluria Foundation (OHF)**



The OHF seeks to support research that will ultimately lead to new diagnostics, treatments, and a cure for Primary Hyperoxaluria and related Hyperoxaluria conditions.

Award Amount: \$200,000 paid over 2 years

Application Deadline: Nov 1, 2016

Website: <http://ohf.org/grants-funding/>

#### **10. Collaborative Awards in Science, Wellcome Trust**

Collaboration promotes the development of new ideas and can bring disciplines together to speed the pace of discovery. The Trust has therefore launched a new Collaborative Award scheme, supporting groups of researchers who are pursuing scientific problems. The Trust encourages applications which propose to carry out interdisciplinary research across our Science, Humanities and Social Sciences, and Innovations funding.

Award Amount: £4 million GBP paid over 5 years

Preliminary Proposal: Aug 22, 2016

Website: <https://wellcome.ac.uk/funding/collaborative-awards-science>